These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 19053961

  • 1. Delayed neovascularization in inflammation-induced corneal neovascularization in interleukin-10-deficient mice.
    Samolov B, Kvanta A, van der Ploeg I.
    Acta Ophthalmol; 2010 Mar; 88(2):251-6. PubMed ID: 19053961
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Role of macrophage migration inhibitory factor in corneal neovascularization.
    Usui T, Yamagami S, Kishimoto S, Seiich Y, Nakayama T, Amano S.
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3545-50. PubMed ID: 17652722
    [Abstract] [Full Text] [Related]

  • 11. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).
    Azar DT.
    Trans Am Ophthalmol Soc; 2006 Aug; 104():264-302. PubMed ID: 17471348
    [Abstract] [Full Text] [Related]

  • 12. Expression of cell adhesion molecules on limbal and neovascular endothelium in corneal inflammatory neovascularization.
    Zhu SN, Dana MR.
    Invest Ophthalmol Vis Sci; 1999 Jun; 40(7):1427-34. PubMed ID: 10359324
    [Abstract] [Full Text] [Related]

  • 13. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization.
    Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B.
    Exp Eye Res; 2000 Apr; 70(4):419-28. PubMed ID: 10865990
    [Abstract] [Full Text] [Related]

  • 14. Impaired angiogenic response in the corneas of mice lacking osteopontin.
    Fujita N, Fujita S, Okada Y, Fujita K, Kitano A, Yamanaka O, Miyamoto T, Kon S, Uede T, Rittling SR, Denhardt DT, Saika S.
    Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):790-4. PubMed ID: 19741245
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Suppression of choroidal neovascularization in lectin-like oxidized low-density lipoprotein receptor type 1-deficient mice.
    Inomata Y, Fukushima M, Hara R, Takahashi E, Honjo M, Koga T, Kawaji T, Satoh H, Takeya M, Sawamura T, Tanihara H.
    Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3970-6. PubMed ID: 19182261
    [Abstract] [Full Text] [Related]

  • 17. The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization.
    Dell S, Peters S, Müther P, Kociok N, Joussen AM.
    Invest Ophthalmol Vis Sci; 2006 May; 47(5):1928-37. PubMed ID: 16639000
    [Abstract] [Full Text] [Related]

  • 18. Impaired angiogenic response in the cornea of mice lacking tenascin C.
    Sumioka T, Fujita N, Kitano A, Okada Y, Saika S.
    Invest Ophthalmol Vis Sci; 2011 Apr 16; 52(5):2462-7. PubMed ID: 21087965
    [Abstract] [Full Text] [Related]

  • 19. Expression of integrins and MMPs during alkaline-burn-induced corneal angiogenesis.
    Zhang H, Li C, Baciu PC.
    Invest Ophthalmol Vis Sci; 2002 Apr 16; 43(4):955-62. PubMed ID: 11923234
    [Abstract] [Full Text] [Related]

  • 20. Nitric oxide synthase-II is expressed in severe corneal alkali burns and inhibits neovascularization.
    Sennlaub F, Courtois Y, Goureau O.
    Invest Ophthalmol Vis Sci; 1999 Nov 16; 40(12):2773-9. PubMed ID: 10549635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.